COVID-19 as a global emergency is over, but the virus itself is not going away. In May 2023, the World Health Organization officially declared that COVID-19 no longer constitutes a public health emergency of international concern. What that means in practical terms: SARS-CoV-2 is transitioning from a pandemic pathogen into a permanent, seasonal respiratory virus, much like the flu. The crisis phase has ended. The virus has not.
What “Endemic” Actually Means
Scientists define endemicity as the long-term persistence of a pathogen in a population at a steady annual level of infection. SARS-CoV-2 is on track to become the fifth endemic human coronavirus, joining four others that most people have never heard of (HKU1, NL63, OC43, and 229E) and that cause a portion of common colds each year. The transition from pandemic to endemic doesn’t mean the virus becomes harmless. It means outbreaks become more predictable, population immunity stabilizes, and the healthcare system can absorb the waves without emergency measures.
Several factors are driving this shift. Most of the world’s population now carries some immunity from prior infection, vaccination, or both. The Omicron-lineage variants currently circulating cause less severe disease on average than earlier strains. And clinical care has improved significantly since 2020. Weekly deaths, hospitalizations, and ICU admissions have all declined dramatically from their peaks.
The 1918 Flu Followed the Same Path
This pattern isn’t new. The 1918 Spanish flu killed tens of millions of people during its pandemic phase from 1918 to 1920. But the H1N1 virus behind it didn’t vanish. It continued causing epidemics with significant mortality through the 1920s. As late as 1951, highly virulent H1N1 strains still emerged, though they stayed geographically limited. The virus accumulated mutations over decades, eventually becoming one of the seasonal influenza strains that circulate every winter today.
SARS-CoV-2 is following a similar trajectory, compressed by modern medicine and widespread vaccination. The expectation is seasonal waves, likely peaking in winter months, with severity that fluctuates year to year depending on which variants are circulating and how recently most people were last exposed.
Why the Virus Keeps Changing
SARS-CoV-2 mutates at a rate that’s actually modest for an RNA virus, roughly five times slower than dengue virus and ten times slower than poliovirus. It has a built-in proofreading mechanism that catches many copying errors. But “modest” is relative. The virus still generates enough mutations to produce new variants regularly, and its enormous global circulation gives it countless opportunities to stumble onto changes that help it evade immunity.
This is why COVID keeps coming back in waves even among people who’ve been infected or vaccinated before. The virus drifts just enough to partially escape existing antibodies, reinfecting people whose immunity has waned. New variant lineages like NB.1.8.1 were detected at increasing rates across multiple regions in early 2025, a reminder that viral evolution is ongoing and will continue indefinitely.
How Long Immunity Lasts
The strongest protection comes from hybrid immunity: a combination of vaccination and at least one prior infection. People with hybrid immunity maintain protective antibody levels for roughly 283 days after their most recent immune-boosting event, whether that’s a vaccine dose or an infection. Antibodies in this group decay with a half-life of about 241 days, meaning levels drop by half every eight months or so.
For comparison, people who received only two vaccine doses without ever being infected see their antibodies decay with a half-life of about 60 days, falling below protective thresholds much faster. Adding a booster dose extends that to around 100 days, but still well short of hybrid immunity. This is the immunological basis for annual boosters: most people’s protection wanes to below meaningful levels somewhere between 6 and 12 months after their last exposure to the virus or a vaccine.
How Well Current Vaccines Work
The 2024-2025 COVID vaccine reduced the risk of hospitalization by about 40%, with protection holding steady through at least 90 to 179 days after the shot. Against the most severe outcomes, including the need for mechanical ventilation or death, effectiveness jumped to 79%.
Those numbers vary by variant. Protection against hospitalization from the KP.3.1.1 variant was 49%, while against the XEC variant it dropped to 34%. Part of that decline reflects timing: people who caught later-circulating variants had gone longer since their vaccination, so waning immunity accounts for some of the difference. The vaccines remain most effective at preventing the worst outcomes, even when they don’t fully block infection.
Treatments Are Getting Better
Antivirals have been a weak spot in the COVID toolkit, partly because the most widely used option, Paxlovid, interacts with a long list of common medications. That makes it risky for many of the people who need it most: organ transplant recipients, cancer patients, and others on complex drug regimens. A next-generation antiviral called ibuzatrelvir is now in late-stage clinical trials. It was designed specifically to avoid those drug interactions, which could make antiviral treatment accessible to a much larger group of high-risk patients.
What Monitoring Looks Like Now
The days of mass individual testing are over in most countries. Public health agencies have shifted toward wastewater surveillance, which detects viral levels in sewage systems and can pick up rising infections in a community before people start showing up at hospitals. This approach catches asymptomatic infections that individual testing misses and provides an early warning system for seasonal surges. The CDC publishes national wastewater trends as a primary tracking tool.
Global surveillance remains uneven. As of mid-2025, test positivity sits around 11% across 73 reporting countries, with the highest activity in the Eastern Mediterranean, South-East Asia, and Western Pacific regions. The Americas, Europe, and Africa are reporting low levels, with positivity rates between 2% and 3%, though pockets of increased activity appear in areas like the Caribbean. A significant gap persists in data from lower-income regions, where reporting on hospitalizations, ICU admissions, and deaths is too limited to fully evaluate the virus’s impact.
The Practical Reality Going Forward
COVID is settling into a pattern that will look familiar to anyone who deals with flu season. Annual waves, updated vaccines, and a background level of infection that rises and falls with the seasons. The CDC now groups COVID with flu and RSV under a single set of respiratory illness guidelines: stay home when sick, consider masking when community levels are high, and seek treatment early if you’re at higher risk for severe illness.
The virus will continue to mutate, reinfections will keep happening, and some years will be worse than others. Vaccination gaps in high-risk groups remain a concern globally. But the combination of widespread immunity, better treatments, and improved surveillance means COVID is unlikely to return to anything resembling its 2020-2021 intensity. The pandemic is over. Living with the virus is what comes next.